Acupoint thread-embedding therapy of regulating governor vessel, dispersing lung, and suppressing reflux for gastroesophageal reflux cough: a randomized controlled trial.
10.13703/j.0255-2930.20241225-k0001
- Author:
Mingjie TANG
1
;
Wen LU
2
;
Xiaoni ZHANG
3
;
Jiawei GAO
3
;
Xinchang WEI
3
;
Jin LU
3
;
Jia ZHU
4
;
Yulu FENG
1
;
Lejing JIAO
1
;
Xiaofang XIA
5
;
Zhi ZHOU
6
;
Zhaoming CHEN
3
Author Information
1. Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
2. Lianyungang First People's Hospital.
3. Department of Acupuncture and Moxibustion, Nanjing Hospital of TCM Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, Jiangsu Province.
4. Jiangsu Provincial Hospital of TCM.
5. Nanjing Gaochun District Hospital of TCM.
6. Nanjing Gulou District Jiangdong Community Health Service Center.
- Publication Type:English Abstract
- Keywords:
acupoint thread-embedding therapy;
gastroesophageal reflux;
gastroesophageal reflux cough;
governor vessel;
randomized controlled trial (RCT)
- MeSH:
Humans;
Acupuncture Points;
Gastroesophageal Reflux/physiopathology*;
Male;
Female;
Cough/physiopathology*;
Middle Aged;
Aged;
Acupuncture Therapy;
Adult;
Treatment Outcome;
Lung/physiopathology*;
Meridians
- From:
Chinese Acupuncture & Moxibustion
2025;45(8):1047-1052
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy of acupoint thread-embedding therapy of regulating governor vessel, dispersing lung, and suppressing reflux for gastroesophageal reflux cough (GERC).
METHODS:A total of 120 GERC patients were randomly assigned to an observation group (60 cases, 1 case dropped out) and a control group (60 cases, 1 case was eliminated). The observation group received acupoint thread-embedding treatment at positive response points of governor vessel. If no such points were detected, the following acupoints were used: Dazhui (GV14), Fenghu (Extra), Shendao (GV11), Lingtai (GV10), and Zhiyang (GV9). Treatment was administered once every two weeks. The control group received oral rabeprazole enteric capsules at 20 mg twice daily. All the treatment was given for 6 weeks. Clinical outcomes were assessed using cough symptom score, reflux disease questionnaire (RDQ) score, and Leicester cough questionnaire (LCQ) score before and after treatment in the two groups. Clinical efficacy was also compared between the two groups.
RESULTS:After treatment, both groups showed decreased cough symptom scores and the each item scores and total scores of RDQ (P<0.001), and increased LCQ scores (P<0.001) compare with those before treatment. The observation group exhibited lower cough symptom score and chest pain, reflux and total score of RDQ, and higher LCQ score compared to those in the control group (P<0.05). The total effective rate in the observation group was 94.9% (56/59), which was higher than 84.7% (50/59) in the control group (P<0.05).
CONCLUSION:Acupoint thread-embedding therapy of regulating governor vessel, dispersing lung, and suppressing reflux could effectively alleviate cough and reflux symptoms in patients with GERC and improve their quality of life.
